Search

Displaying results 7021 - 7030 of 8967 in total
  1. Drug

    Tariquidar

    go.drugbank.com/drugs/DB06240
    Investigational

  2. Drug

    Ginsenoside Rg1

    go.drugbank.com/drugs/DB06750
    ExperimentalNutraceutical

    Because ginsenosides appear to affect multiple pathways, their effects are complex and difficult to isolate. Rg1 Appears to be most abundant in Panax ginseng (Chinese/Korean Ginseng).

  3. Drug

    Lasalocid

    go.drugbank.com/drugs/DB11423
    ExperimentalVet approved

    It is produced by strains of _Streptomyces lasaliensis_.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Dihydroxyacetone phosphate

    go.drugbank.com/drugs/DB04326
    Investigational

    Dihydroxyacetone phosphate has been investigated for the treatment of Lymphoma, Large-Cell, Diffuse.

  5. Drug

    Milvexian

    go.drugbank.com/drugs/DB16233
    Investigational

    Milvexian is under investigation in clinical trial NCT03766581 (A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel).

  6. Drug

    Tilsotolimod

    go.drugbank.com/drugs/DB16341
    Investigational

    Tilsotolimod is under investigation in clinical trial NCT03865082 (Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)).

  7. Drug

    WP-1122

    go.drugbank.com/drugs/DB17192
    Investigational

    It was granted FDA orphan designation for the treatment of glioblastoma multiforme.[L47361]

    Synonyms: 3,6-di-O-acetyl-2-deoxy-D-glucopyranose
  8. Drug

    Squaric acid dibutyl ester

    go.drugbank.com/drugs/DB12223
    Investigational

    Squaric acid dibutyl ester is under investigation in clinical trial NCT01971385 (Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis).

  9. Drug

    GLB-005

    go.drugbank.com/drugs/DB32797
    Experimental

    GLB-005 is a molecular glue degrader targeting WIZ and is being investigated for treatment of sickle cell disease and β-thalassemia.[L56125, L56126, L56128]

  10. Drug

    NTLA-2002

    go.drugbank.com/drugs/DB17597
    Investigational

    It is an investigational therapy designed to knock out the target gene kallikrein B1 (KLKB1) to reduce plasma kallikrein activity, thereby preventing hereditary angioedema attacks.[L45738]